Immunotherapy of Hematological Malignancies: The State of the Art
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 1127
Special Issue Editors
Interests: pediatric hematology; bone marrow transplantation; bleeding disorders; coagulation disorders; general pediatrics
Special Issues, Collections and Topics in MDPI journals
Interests: hematological malignancies; clinical hematology; flow cytometry; lymphoma; cancer diagnostics; cell culture; liver diseases; hematologic diseases; multiple myeloma; chemotherapy
Special Issue Information
Dear Colleagues,
Chemotherapy is not always effective enough and can have significant side effects; therefore, it is not indicated in some categories of patients (especially the elderly) due to its toxicities and their comorbidities. These are arguments that led to the emergence and development of immunotherapy. Its results have radically improved the evolution of many oncohematological diseases, and this trend continues in parallel with the improvement of production technologies and the expansion of the product range. Such types of immunotherapies are naked or ordinary monoclonal antibodies, antibody-drug conjugates, bi-specific T-cell engagers, adoptive cell transfer, including chimeric antigen receptor T-cells and chimeric antigen receptor-engineered natural killer cells, and immune checkpoint inhibitors. Unfortunately, the increasing use of immunotherapy and immunochemotherapy has dramatically increased the frequency of side effects, including life-threatening clinical manifestations and significant immunosuppression (with risk of infection or a new neoplasm).
Finding a balance between targeted immuno-chemotherapy and protecting the patient's immune system is the key to obtaining good results with the lowest possible risk of infections and secondary neoplasms.
This Special Issue, “Immunotherapy of Hematological Malignancies: The State of the Art", aims to provide an overview of current and developing immunotherapy treatments, endeavoring to give some answers to the many questions and concerns that exist and to facilitate the emergence of new research directions to improve therapeutic results.
Prof. Dr. Anca Colita
Prof. Dr. Romeo Gabriel Mihaila
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody-drug conjugates
- bispecific antibodies
- chimeric antigen receptor-engineered natural killer cell
- chimeric antigen receptor T-cells
- cytokine release syndrome
- immune checkpoint in-hibitors
- immunosuppression
- immunotherapy
- monoclonal antibodies
- neurotoxicities
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
